Esperion Therapeutics, Inc. (NASDAQ:ESPR) was upgraded by equities researchers at Jefferies Group LLC from a “hold” rating to a “buy” rating in a research note issued on Tuesday, The Fly reports.

A number of other analysts have also issued reports on ESPR. Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 1st. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Deutsche Bank AG initiated coverage on Esperion Therapeutics in a report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price objective on the stock. Finally, BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, June 25th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Esperion Therapeutics currently has an average rating of “Buy” and an average target price of $39.16.

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 15.41% during trading on Tuesday, reaching $52.13. 4,147,332 shares of the company’s stock were exchanged. The firm’s market capitalization is $1.18 billion. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $57.38. The company’s 50-day moving average price is $44.47 and its 200 day moving average price is $33.65.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by $0.30. During the same quarter in the prior year, the firm earned ($0.62) EPS. Analysts predict that Esperion Therapeutics will post ($6.69) EPS for the current fiscal year.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/esperion-therapeutics-inc-espr-upgraded-by-jefferies-group-llc-to-buy.html.

A number of institutional investors have recently made changes to their positions in ESPR. Quantbot Technologies LP bought a new position in Esperion Therapeutics during the first quarter worth approximately $158,000. C WorldWide Group Holding A S bought a new position in Esperion Therapeutics during the first quarter worth approximately $162,000. Princeton Alpha Management LP bought a new position in Esperion Therapeutics during the first quarter worth approximately $205,000. Bank of Montreal Can increased its position in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the period. Finally, Aperio Group LLC bought a new position in Esperion Therapeutics during the second quarter worth approximately $249,000. Institutional investors own 85.20% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

The Fly

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.